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beta-blockade will suppress renin, it does so inefficiently compared
to ACE inhibition. To presume that beta-blocker addition follow-
ing an ACE inhibitor is the same as the addition of an ACE
inhibitor after a beta-blocker is simply wrong. To suggest that
beta-blockade should be given first and an ACE inhibitor not at all
is equally wrong. To presume that an ACE inhibitor after a
beta-blocker would be ineffectual or of little value from the limited
work of Sliwa and colleagues is at best an overstatement.
Second, the patients in this study are likely to be Africans (a
critical missing statement that avoided detection in the review
process?). This patient group, in addition to being rarely studied,
is at least well known to show reduced response to renin system
blockade. Furthermore, the subjects are unusual in that they are all
suggested to have idiopathic dilated cardiomyopathy. This would
be rare in a Westernized cohort relevant to the U.S. or Europe.
We believe Dr. Leier should not fear for the efficacy of ACE
inhibitor therapy in systolic LV dysfunction, although he is very
correct to draw attention to the significance of order effects in
therapeutics. These have been well recognized in cardiovascular
pharmacology for over a century. A more temperate interpretation
of Silwa’s study results would be that beta-blockade should be
introduced in patients with systolic heart failure as soon as possible
after diagnosis, and certainly without a six-month delay. Physicians
might reasonably initiate a beta-blocker prior to an ACE inhibitor
in those patients with euvolemic “dry” heart failure, and an ACE
inhibitor first in those with persisting congestion, with plans to add
a beta-blocker as soon as the congestion has resolved.
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REPLY
We appreciate the interest in our recently published study (1). Dr.
Law raises several concerns, some of which we find puzzling.
Baragwanath is the only hospital serving a population of some
three million; with a bed capacity of 3,300, it is the largest hospital
in the Southern Hemisphere and has a cardiac clinic that sees some
25,000 patients annually. In this context, it is not difficult to
understand how 100 or more new patients with idiopathic dilated
cardiomyopathy might be recruited each year. The majority of
these patients receive workup and therapy as outpatients. For us,
and surely for many other busy units, these patients represent “real
clinical practice.” Dr. Law questions the six-month delay in
starting carvedilol in the “ACE-I first” group. We cannot under-
stand his concern as this in essence was the design of the study to
answer the issue at hand. Our study and the CIBIS-III trial have
chosen monotherapy with an ACE inhibitor versus a beta-blocker
for six months followed by combination of both agents to study the
impact of the individual and subsequent combination effect of each
drug on left ventricular (LV) function. There is no direct scientific
evidence of the exact duration when an impact on remodeling of
the left ventricle can be expected. However, it will be several
months rather than a few weeks.
The question as to the mechanism of benefit is speculative but
does not detract from the important finding that the beta-blocker–
first strategy was superior. The notion that beta-blockade may be
harmful when initiated in patients with advanced heart failure was
clearly dispelled by the results of the COPERNICUS study (2),
which showed carvedilol to be beneficial even in class IV heart
failure.
We fully agree with the sentiments of Dr. MacFadyen et al.
regarding the pharmacologic importance of the sequence in which
drug therapy is initiated, especially in a condition such as heart
failure, where multidrug therapy is the rule and where optimal
doses may be severely handicapped by hypotension. Both ethnicity
and the response to drug therapy are important issues, and it is
notable that the majority of our patients were black Africans who
have been shown to respond differently to ACE inhibitors in the
setting of hypertension and possibly also in heart failure (3). That
is why we believe it is important that further investigation in larger
studies, using different ethnic groups and other etiologies of heart
failure, such as ischemic cardiomyopathy, be undertaken, first, to
confirm our results and, second, to determine their generalizability.
The efforts of the CIBIS-III investigators (4) and their comments
on our findings are appreciated and we eagerly await publication of
their results.
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